Objectif Kidney dialysis and transplantation are life saving but expensive forms of treatment for patients with End Stage Renal Disease. Increasingly older patients and more importantly those with coexisting illnesses (eg heart disease) are receiving such Renal Replacement Therapy (RRT) in most Western and some Eastern European countries. Since the prevalence of such comorbidity varies from country to country, published data comparing survival on RRT are open to misinterpretation. The main aim of RRT is preservation of life, however the control of associated medical conditions is also important. Our current Biomed 1 project aims to determine, using a risk stratification protocol, the effect of age and comorbidity on survival on RRT and to establish and monitor protocols for the clinical management of such patients in centres in five countries in Western Europe. We now wish to include St petersburg and Sofia in our study and determine their acceptance rate of patients for RRT and whether the proportions in the low, medium and high risk categories (according to age and comorbidity) are different from those in the five Western European countries in the study. our current Biomed 1 project is developing and monitoring protocols for the management of anaemia, bone disease and CMV infection in patients with End Stage Renal Disease. In view of the time constraints the participants from St petersburg and Sofia will fill up data collection forms for the data required before the implementation of the protocols. In this way their basic data will be available for comparison with those of the other centres. In addition they will attend the Plenary meeting at which results are discussed with aview to considering developing such guidelines for the care of the patients in their own centres. Overall the inclusion of these Eastern European centres will a) allow us to improve-our risk stratification protocol for use throughout Western and Eastern Europe b) allow us to strengthen the results obtained from the centres (Tirana and Budapest) incorporated during the PECO 93 initiative and c) enable our clinical management guidelines to have wider relevance throughout Europe and permit our health care systems to be better organised, managed and financed, particularly in the areas working within financial constraints. Programme(s) IC-PECO/COPERNICUS - Scientific and technological cooperation between the European Community and European non-member countries, 1992- Thème(s) 0201 - CEEC participation in BIOMEDICAL AND HEALTH RESEARCH programme Appel à propositions Data not available Régime de financement CSC - Cost-sharing contracts Coordinateur UNIVERSITY OF ABERDEEN Contribution de l’UE Aucune donnée Adresse Polwarth Building, Foresterhill AB25 2ZD ABERDEEN Royaume-Uni Voir sur la carte Coût total Aucune donnée Participants (1) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire Ministry of Health of the Russian Federation Russie Contribution de l’UE Aucune donnée Adresse 6/8,Leo Tolstoy 101953 St Petersburg Voir sur la carte Coût total Aucune donnée
